1
EXHIBIT 4.8
CALL OPTION AGREEMENT
This CALL OPTION AGREEMENT, dated as of the ___ day of August, 2001,
(the "Agreement") is entered into by and among AMERICAN BIOGENETIC SCIENCES,
INC., a Delaware corporation (the "Company"), and the investors signatories
hereto (individually, a "Holder," and collectively, the "Holders").
RECITALS
WHEREAS, the Company has previously issued certain Series A Convertible
Preferred Stock (the "Series A Preferred Stock") and related Series A Warrants
(the "Series A Warrants"), as to which 6,000,000 of said Series A Warrants were
amended ("Amended Series A Warrants");
WHEREAS, each of the Holders is a party to that certain Securities
Purchase Agreement, dated as of the date hereof (the "Series B Securities
Purchase Agreement") with the Company, providing, INTER ALIA, for the purchase
by certain of the Holders of the Company's Series B Convertible Preferred Stock
(the "Series B Preferred Stock") and Series B Warrants and the amendment of the
Company's Restated Certificate of Incorporation to amend the terms of the Series
A Preferred Stock held by certain other of the Holders and to designate the
Series B Preferred Stock out of the Company's undesignated Preferred Stock;
WHEREAS, in conjunction with the issuance of the Series B Preferred
Shares and the Series B Warrants, the Company has further agreed to grant to the
Holders certain Revenue Participation Notes, pursuant to which a portion of any
royalty payments received by the Company under a certain Exclusive License
Agreement dated January 27, 2000, as it may be amended from time to time between
the Company and Abbott Laboratories (the "Exclusive License Agreement"), will be
paid to the Holders, and Holders have agreed to grant to the Company the right
to redeem or repurchase shares of the Series A Preferred Stock and Series B
Preferred Stock and cancel and redeem the Series A Warrants and Series B
Warrants, all as more fully described herein; and
WHEREAS, the parties hereto desire to set forth certain matters to
which they have agreed relating to the foregoing;
NOW, THEREFORE, in consideration of the mutual promises, covenants and
conditions hereinafter set forth and for other good and valuable consideration
the Company, each Holder, severally and not jointly, hereby agree as follows:
Section 1. CERTAIN DEFINITIONS.
(a) As used in this Agreement, the following terms shall have the
following respective meanings:
"Charter Amendment" means the Amended and Restated Certificate of
Incorporation filed pursuant to the Series B Securities Purchase Agreement.
Call Option Agreement
Execution Copy
2
"Holder" means each person signatory hereto who upon completion of the
sale under the Securities Purchase Agreement shall be a holder of Preferred
Stock, Warrants, and a Revenue Participation Note, and shall also include all
successors and assigns of such person's interests therein.
"Preferred Stock" means a collective reference to the Series A
Preferred Stock and the Series B Preferred Stock.
"Revenue Participation Note" means any of that series of Revenue
Participation Notes issued by the Company pursuant to the Series B Securities
Purchase Agreement, evidencing the right to receive certain royalty payments
received by the Company under the Exclusive License Agreement.
"Warrants" means a collective reference to the Series A Warrants and
the Series B Warrants.
(b) Any other term capitalized herein and not defined herein shall have the
meaning specified in the Revenue Participation Notes and the Series B Securities
Purchase Agreement.
Section 2. RIGHT TO CALL PREFERRED STOCK AND WARRANTS.
(a) RIGHT TO CALL. Following any payment by the Company of a Fractional
Amount to any Holder of a Revenue Participation Note, the Company shall have the
right, but not the obligation, to (i) redeem such number of shares of such
Holder's Preferred Stock, or the Preferred Stock then held by such Holder's
predecessor in interest, as can be redeemed at the original purchase price
thereof for an amount equal to one-fifth (1/5th) of the amount of such
Fractional Amount paid to Holder and (ii) under the related Warrant, cancel the
right to purchase 1000 shares of Common Stock for each share of Preferred Stock
redeemed pursuant to clause (i) hereof, in exchange for a payment of $0.0125 per
Warrant share.
(b) PRIORITY. Redemptions under this Section (including redemptions in
part) shall be made from the holders of Preferred Stock based upon the amount
paid to each Holder (or such Holder's successor in interest) under the Revenue
Participation Notes. However, all shares of Series A Preferred Stock subject to
this Agreement must be redeemed prior to any redemption of the Series B
Preferred Stock, and all Amended Series A Warrants must be cancelled hereunder
before any Series B Warrants are cancelled.
(c) NOTICE. Notice of any election to redeem Preferred Stock or cancel
a Warrant shall be given by the Company to each holder to be redeemed at least 5
days prior to date on which it proposes to redeem the stock or cancel the
Warrant (the "Redemption Date"). Notice shall be given to the holders of record
at their respective addresses appearing on the books of the Company or given by
such holder to the Company for the purposes of notice, or if no such address
appears or is given, at the principal office of the Company. Such notice shall
state the Redemption Date to which such notice relates, the number of shares of
Preferred Stock to be
Call Option Agreement
Execution Copy
2
3
redeemed or Warrants to be cancelled from all holders thereof and from such
holder, and the date on which such holder's right to convert into Common
Stock pursuant to the Charter Amendment will terminate as to such shares. On the
Redemption Date, each holder of shares of Preferred Stock shall surrender the
certificate evidencing such shares to the Company at the place designated in the
notice. If less than all the shares represented by any such surrendered
certificate have been or are being redeemed, a new certificate shall be issued
representing the unredeemed shares.
(d) FUNDS AVAILABLE. Payments made to holders of the Revenue
Participation Notes may be used to redeem shares of Preferred Stock only to the
extent of funds legally available for redemption on any such Redemption Date. To
the extent payments made to holders of Preferred Stock pursuant to Revenue
Participation Notes exceed the amount of the funds legally available for
redemption under applicable law, the payments may be used to redeem from among
the holders of the Preferred Stock the number of shares of Preferred Stock
having an aggregate redemption price as nearly equal as possible to the amount
of the funds available therefor. For the purpose of determining whether funds
are legally available for redemption of shares of Preferred Stock as provided
herein, the Company shall value its assets at the highest amount reasonably
permissible under applicable law.
(e) RIGHTS CEASE. From and after the Redemption Date, and upon payment
by the Company of the redemption price then, notwithstanding that the
certificates evidencing any shares of Preferred Stock so called for redemption
shall not have been surrendered, all rights of the holders thereof with respect
to the shares so called for redemption shall forthwith after such date cease and
terminate.
Section 3. MISCELLANEOUS.
(a) NOTICES. All notices, requests, consents and other communications
hereunder shall be in writing, shall be addressed to the receiving party's
address set forth in Section 10.1 of the Series B Securities Purchase Agreement
or to such other address as a party may designate by notice hereunder, and shall
be either (i) delivered by hand, (ii) made by telecopy or facsimile
transmission, (iii) sent by recognized national overnight courier service, or
(iv) sent by registered mail, return receipt requested, postage prepaid. All
notices, requests, consents and other communications hereunder shall be deemed
to have been given either (i) if by hand, at the time of the delivery thereof to
the receiving party at the address of such party set forth above, (ii) if made
by telecopy or facsimile transmission, on the next business day after the time
that receipt thereof has been acknowledged by electronic confirmation or
otherwise, (iii) if sent by overnight courier, on the next business day
following the day such notice is delivered to the courier service, or (iv) if
sent by registered mail, on the fifth business day following the day such
mailing is made.
(b) ENTIRE AGREEMENT. This Agreement, together with the Securities
Purchase Agreement and such other documents as are referred to therein, embodies
the entire agreement and understanding between the parties hereto with respect
to the subject matter hereof and supersedes all prior oral or written agreements
and understandings relating to the subject matter hereof. No statement,
representation, warranty, covenant or agreement of any kind not expressly
Call Option Agreement
Execution Copy
3
4
set forth in this Agreement shall affect, or be used to interpret, change or
restrict, the express terms and provisions of this Agreement.
(c) AMENDMENTS. The terms and provisions of the Agreement may be
modified, amended or waived, or consent for the departure therefrom granted,
only by written agreement of the Company; and Holders holding in the aggregate a
majority of the Fractional Percentage held by all Holders of Revenue
Participation Notes. No such waiver or consent, in either case, shall be deemed
to be or shall constitute a waiver or consent with respect to any other terms or
provisions of this Agreement, whether or not similar. Each such waiver or
consent, in either case, shall be effective only in the specific instance and
for the purpose for which it was given, and shall not constitute a continuing
waiver or consent.
(d) ASSIGNMENT. This Agreement and any or all of the rights and
obligations of a party hereunder may be assigned, delegated, sold, transferred
or otherwise disposed of by any means, including by voluntary transfer,
operation of law or otherwise, to any third person without the prior written
consent of the other parties hereto. Any such assignment, however, shall only be
effective if the assignor provides the Company with two business days' prior
written notice of such assignment. The Company's right to redeem Preferred Stock
or cancel the related Warrants shall survive each such assignment, whether or
not the related Preferred Stock or Warrant are transferred together with any
transfer of a Revenue Participation Note. Each party shall be responsible for
the compliance by its affiliates with the terms and conditions of this
Agreement.
(e) BENEFIT. All statements, representations, warranties, covenants and
agreements in this Agreement shall be binding on the parties hereto and shall
inure to the benefit of the respective successors and permitted assigns of each
party hereto. Nothing in this Agreement shall be construed to create any rights
or obligations except among the parties hereto, and no person or entity shall be
regarded as a third-party beneficiary of this Agreement.
(f) GOVERNING LAW. This Agreement and the rights and obligations of the
parties hereunder shall be construed in accordance with and governed by the law
of the State of New York except that the law of the State of Delaware shall be
applicable with respect to corporate matters.
(g) SEVERABILITY. In the event that any court of competent jurisdiction
shall determine that any provision, or any portion thereof, contained in this
Agreement shall be unreasonable or unenforceable in any respect, then such
provision shall be deemed limited to the extent that such court deems it
reasonable and enforceable, and as so limited shall remain in full force and
effect. In the event that such court shall deem any such provision, or portion
thereof, wholly unenforceable, the remaining provisions of this Agreement shall
be interpreted as if such provision were so excluded and shall nevertheless
remain in full force and effect.
(h) HEADINGS AND CAPTIONS. The headings and captions of the various
subdivisions of this Agreement are for convenience of reference only and shall
in no way modify, or affect the meaning or construction of any of the terms or
provisions hereof.
Call Option Agreement
Execution Copy
4
5
(i) NO WAIVER OF RIGHTS, POWERS AND REMEDIES. No failure or delay by a
party hereto in exercising any right, power or remedy under this Agreement, and
no course of dealing between the parties hereto, shall operate as a waiver of
any such right, power or remedy of the party. No single or partial exercise of
any right, power or remedy under this Agreement by a party hereto, nor any
abandonment or discontinuance of steps to enforce any such right, power or
remedy, shall preclude such party from any other or further exercise thereof or
the exercise of any other right, power or remedy hereunder. The election of any
remedy by a party hereto shall not constitute a waiver of the right of such
party to pursue other available remedies. No notice to or demand on a party not
expressly required under this Agreement shall entitle the party receiving such
notice or demand to any other or further notice or demand in similar or other
circumstances or constitute a waiver of the rights of the party giving such
notice or demand to any other or further action in any circumstances without
such notice or demand.
(j) COUNTERPARTS. This Agreement may be executed in one or more
counterparts, and by different parties hereto on separate counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.
(k) FURTHER ASSURANCES. In case any further action is necessary or
desirable to carry out the purposes of this Agreement, the Company and the
Holders will take such further action as the other party may reasonably request,
all at the sole cost and expense of the requesting party.
[REST OF PAGE INTENTIONALLY LEFT BLANK]
Call Option Agreement
Execution Copy
5
6
IN WITNESS WHEREOF, the undersigned have executed this Call Option
Agreement as of this ___ day of August, 2001.
AMERICAN BIOGENETIC SCIENCES, INC.
By:
--------------------------------------
Name: Josef C. Schoell
Title: President, COO and CFO
HOLDERS:
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF PARTNERS L.P., its General Partner
By: BVF, INC., its General Partner
By: _____________________________
Mark N. Lampert
President
BIOTECHNOLOGY VALUE FUND II, L.P.
By: BVF PARTNERS L.P., its General Partner
By: BVF, INC., its General Partner
By: _____________________________
Mark N. Lampert
President
INVESTMENT 10 L.L.C.
By: BVF PARTNERS, L.P., its Investment
Advisor
By: BVF, INC., its General Partner
By: _____________________________
Mark N. Lampert
President
BVF INVESTMENTS, L.L.C.
By: BVF PARTNERS, L.P., its Investment
Advisor
By: BVF, INC., its General Partner
By: _____________________________
Mark N. Lampert
President
Call Option Agreement
Execution Copy
6